Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 21, 2021 08:00 ET | Source: Calithera Biosciences, Inc.

Calithera Biosciences to Present First Clinical Data from Development Program for Arginase Inhibitor CB-280 at NACFC 2021

SOUTH SAN FRANCISCO, Calif., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage biopharmaceutical company, today announced that data from its Phase 1b...
October 18, 2021 16:07 ET | Source: Calithera Biosciences, Inc.

Calithera Expands Oncology Pipeline with Acquisition of Two Clinical-Stage Assets from Takeda Pharmaceuticals

-- TORC 1/2 inhibitor sapanisertib and SYK inhibitor mivavotinib strengthen Company’s precision oncology pipeline -- -- Calithera will initiate Phase 2 clinical trials of sapanisertib and mivavotinib...
September 08, 2021 07:00 ET | Source: Calithera Biosciences, Inc.

Calithera Biosciences to Present Telaglenastat KEAPSAKE Trial in Progress Poster at the IASLC 2021 World Conference on Lung Cancer

SOUTH SAN FRANCISCO, Calif., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage biotechnology company focused on discovering and developing novel...
September 02, 2021 07:00 ET | Source: Calithera Biosciences, Inc.

Calithera Biosciences to Participate in Two Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a fully-integrated clinical stage biotechnology company focused on discovering and...
August 05, 2021 16:05 ET | Source: Calithera Biosciences, Inc.

Calithera Biosciences Reports Second Quarter 2021 Financial Results and Recent Highlights

-- Cash, Cash Equivalents and Investments Totaled $92.2 million as of June 30, 2021 -- -- Conference Call and Webcast Scheduled for 2:00 p.m. PT on August 5, 2021-- SOUTH SAN FRANCISCO, Calif., Aug....
July 29, 2021 07:00 ET | Source: Calithera Biosciences, Inc.

Calithera Biosciences to Report Second Quarter 2021 Financial Results on Thursday, August 5, 2021

SOUTH SAN FRANCISCO, Calif., July 29, 2021 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a fully-integrated clinical-stage biotechnology company focused on discovering and...
June 07, 2021 08:00 ET | Source: Calithera Biosciences, Inc.

Final Data from Calithera Biosciences’ Phase 2 CANTATA Study in Renal Cell Carcinoma Presented at 2021 ASCO Annual Meeting

SOUTH SAN FRANCISCO, Calif., June 07, 2021 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage biotechnology company focused on discovering and developing novel...
May 27, 2021 07:00 ET | Source: Calithera Biosciences, Inc.

Calithera to Present at the Jefferies 2021 Virtual Healthcare Conference

SOUTH SAN FRANCISCO, Calif., May 27, 2021 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage biotechnology company focused on discovering and developing novel small...
May 17, 2021 08:00 ET | Source: Calithera Biosciences, Inc.

Calithera Biosciences and Antengene Enter Worldwide License Agreement for Development & Commercialization of CB-708

--CB-708 is an oral small molecule inhibitor of CD73 in preclinical development for oncology--Antengene is granted exclusive rights to develop and commercialize asset discovered and initially...
May 06, 2021 16:05 ET | Source: Calithera Biosciences, Inc.

Calithera Biosciences Reports First Quarter 2021 Financial Results and Recent Highlights

--$102.9 Million in Cash and Investments at March 31, 2021-- -- Conference Call and Webcast Scheduled for 2:00 p.m. PT on May 6, 2021-- SOUTH SAN FRANCISCO, Calif., May 06, 2021 (GLOBE...